Form 4: MPM BioVentures Sells 295K HOWL Shares

MPM BioVentures, a 10% owner and director of Werewolf Therapeutics, Inc., reported selling 295,043 shares of common stock across three transactions in late October and early November 2025.

Summary

• MPM BioVentures 2014, L.P., along with several related entities, reported the sale of 295,043 shares of Werewolf Therapeutics, Inc. (HOWL) common stock.
• The transactions occurred on October 30, 2025, October 31, 2025, and November 3, 2025.
• On October 30, 2025, 86,936 shares were sold at a weighted average price of $1.43 per share.
• On October 31, 2025, 114,044 shares were sold at a weighted average price of $1.28 per share.
• On November 3, 2025, 94,063 shares were sold at a weighted average price of $1.29 per share.
• These sales were executed pursuant to a Rule 10b5-1 plan established on September 24, 2025.
• Following these transactions, the reporting persons indirectly beneficially own 6,147,610 shares of common stock.
• The shares were sold by various MPM entities, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P.

Sentiment

Score: 3

Explanation: The sale of a substantial number of shares by a 10% owner and director group, even under a pre-established 10b5-1 plan, typically generates negative sentiment as it can be interpreted as a lack of confidence in the company's future prospects or a strategic divestment. The pre-planned nature mitigates some of the immediate negative shock but does not eliminate the underlying signal of reduced insider exposure.

Negatives

• Significant insider selling by a 10% owner and director group can be interpreted as a negative signal regarding the company's future prospects or valuation.
• The reduction in beneficial ownership by a major institutional investor may lead to decreased investor confidence.

Risks

• Potential negative market perception and downward pressure on Werewolf Therapeutics' stock price due to the substantial insider selling.
• The sales, even if pre-planned, could signal a strategic divestment by a knowledgeable investor.

Future Outlook

This Form 4 filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Ansbert Gadicke, Managing Director of MPM BioVentures 2014 LLC, signed the filing on behalf of the various reporting entities, acknowledging the transactions.

Industry Context

This filing reflects an insider transaction by a significant institutional investor in the biotechnology sector. While specific to Werewolf Therapeutics, such sales by major shareholders can sometimes be interpreted by the market as a signal regarding the company's near-term prospects or the broader investment climate within the biotech industry, especially for early-stage or clinical-stage companies.

Comparison to Industry Standards

• N/A. This Form 4 reports insider selling, which is not directly comparable to industry-wide performance metrics or project results. It reflects a specific investment decision by a 10% owner rather than operational performance against industry benchmarks.

Related Party Transactions

• The transactions involve multiple entities related to MPM BioVentures 2014, L.P., including MPM Asset Management LLC, MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P. These entities are interconnected through general partners and managers, with Ansbert Gadicke being a key figure across them.

Stakeholder Impact

• Shareholders may perceive the significant insider selling by a 10% owner and director group as a negative signal, potentially leading to downward pressure on the stock price.
• The transactions were executed under a Rule 10b5-1 plan, which indicates a pre-scheduled sale, potentially mitigating some immediate negative interpretation compared to an unscheduled sale.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request from the Issuer, any security holder, or the SEC staff.

Key Dates

Recommendation

The significant sale of shares by a 10% owner and director group, even if pre-planned under a 10b5-1, often signals a lack of conviction or a strategic move away from the investment. This insider selling could exert downward pressure on the stock price and suggests that the reporting persons see better opportunities elsewhere or anticipate challenges for Werewolf Therapeutics. Investors should consider this a negative signal.

Keywords

Werewolf Therapeutics, HOWL, MPM BioVentures, Insider Selling, Form 4, Biotechnology, Stock Sale, 10b5-1 Plan, Ansbert Gadicke, Institutional Investor